RBCC to Drive Growth Through Personalized Medicine

  RBCC to Drive Growth Through Personalized Medicine

Business Wire

NOKOMIS, Fla. -- May 30, 2013

As part of its mission to capture a share of the fast-growing, $232 billion
personalized medicine market, Rainbow Coral Corp. (OTCBB: RBCC) is making
plans to empower patients to demand better care through a potent combination
of innovation and education.

By delivering new technologies in the sectors of the personalized medicine
field poised for the most growth—including companion diagnostics—RBCC hopes to
arm patients with more effective and efficient treatment options than ever
before. But bringing new ideas and products to the marketplace is only one
piece of the company’s strategy for expansion, says RBCC CEO Patrick Brown.

“Our ultimate goal is to help spur patient-driven demand for personalized
medicine,” Brown said. “That requires not just delivering new innovations, but
helping to educate patients on these promising new treatment options. That’s
why we’re developing a comprehensive media and marketing strategy.”

The personalized medicine market in the U.S. is ripe for expansion, with
PricewaterhouseCoopers predicting that the sector could grow to as much as
$452 billion by 2015. One of the fastest-growing fields in the market is
companion diagnostics, which could grow to as large as $42 billion by 2015,
according to industry analysts TriMarkPublications.com.

RBCC has formed a biotech subsidiary, Rainbow BioSciences, to market and
develop new medical and research technology innovations to compete alongside
companies such as Bristol Myers Squibb Co. (NYSE:BMY),Biogen Idec Inc.
(NASDAQ:BIIB), Abbott Laboratories (NYSE:ABT) and Amgen Inc. (NASDAQ:AMGN).

For more information on RBCC’s other biotech initiatives, please
visitwww.rainbowbiosciences.com/investors.html.

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp.
(OTCBB:RBCC). The Company continually seeks out new partnerships with
biotechnology developers to deliver profitable new medical technologies and
innovations. For more information on our growth-oriented business initiatives,
please visitwww.RainbowBioSciences.com. For investment information and
performance data on the Company, please
visitwww.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: This news release contains forward-looking information within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, including statements
that include the words "believes," "expects," "anticipate" or similar
expressions. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, performance
or achievements of the Company to differ materially from those expressed or
implied by such forward-looking statements. In addition, description of
anyone's past success, either financial or strategic, is no guarantee of
future success. This news release speaks as of the date first set forth above
and the Company assumes no responsibility to update the information included
herein for events occurring after the date hereof.

Contact:

Rainbow Coral Corp.
Patrick Brown, 850-269-7230
President and CEO
info@rainbowcoral.com